ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,421 to 1,440 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period27 of 3,107

21 of 3,101

0.2 points

-0.3 to 0.6

6,208NCT01462344

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

FSC DPI vs FP DPI: serious adverse events56 of 3,107

54 of 3,101

0.1 points

-0.6 to 0.7

6,208NCT01462344

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Febuxostat vs Allopurinol: deaths from any cause243 of 3,098

199 of 3,092

1.4 points

0.1 to 2.7

6,190NCT01101035

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Febuxostat vs Allopurinol: serious adverse events1,046 of 3,098

995 of 3,092

1.6 points

-0.8 to 3.9

6,190NCT01101035

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Dalcetrapib vs Placebo: Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure321 of 3,071

346 of 3,076

-0.8 points

-2.4 to 0.8

6,147NCT02525939

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Dalcetrapib vs Placebo: deaths from any cause182 of 3,071

180 of 3,076

0.1 points

-1.1 to 1.3

6,147NCT02525939

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Dalcetrapib vs Placebo: Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke292 of 3,071

327 of 3,076

-1.1 points

-2.6 to 0.4

6,147NCT02525939

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Dalcetrapib vs Placebo: Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization471 of 3,071

471 of 3,076

0.0 points

-1.8 to 1.8

6,147NCT02525939

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Dalcetrapib vs Placebo: serious adverse events900 of 3,071

923 of 3,076

-0.7 points

-3.0 to 1.6

6,147NCT02525939

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

RZV Group vs Placebo Group: Number of Participants With at Least One Related SAE From First Vaccination (Day 1) up to Study End (Duration of Approximately 2 Years)0 of 3,064

1 of 3,064

-0.0 points

-0.2 to 0.1

6,128NCT04869982

Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

RZV Group vs Placebo Group: deaths from any cause13 of 3,064

11 of 3,064

0.1 points

-0.3 to 0.4

6,128NCT04869982

Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

RZV Group vs Placebo Group: serious adverse events90 of 3,064

94 of 3,064

-0.1 points

-1.0 to 0.7

6,128NCT04869982

Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

Vericiguat vs Placebo: deaths from any cause392 of 3,053

455 of 3,052

-2.1 points

-3.8 to -0.3

6,105NCT05093933

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

Fluarix Quadrivalent 60 ug vs mRNA-1010 50 ug: deaths from any cause18 of 3,057

10 of 3,045

0.3 points

-0.1 to 0.6

6,102NCT05415462

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Vericiguat vs Placebo: serious adverse events732 of 3,049

766 of 3,049

-1.1 points

-3.3 to 1.0

6,098NCT05093933

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

Expectant Management vs Elective Induction of Labor: Number of Infants With Neonatal Hypoxic-ischemic Encelphalopathy (Component of Primary Outcome)20 of 3,037

14 of 3,059

0.2 points

-0.2 to 0.6

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: Number of Participants With Cesarean Delivery674 of 3,037

569 of 3,059

3.6 points

1.6 to 5.6

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: Number of Infants With Apgar Score ≤3 at 5 Minutes (Component of Primary Outcome)18 of 3,037

12 of 3,059

0.2 points

-0.2 to 0.6

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: Number of Participants Experiencing Hypertensive Disorder of Pregnancy427 of 3,037

277 of 3,059

5.0 points

3.4 to 6.6

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Expectant Management vs Elective Induction of Labor: Participants Who Had Operative Vaginal Delivery258 of 3,037

222 of 3,059

1.2 points

-0.1 to 2.6

6,096NCT01990612

A Randomized Trial of Induction Versus Expectant Management

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=72

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01462344-d2e8b2c9",
        "title": "FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period",
        "summary": "27 of 3107 against 21 of 3101; risk difference 0.2 points, 95% interval -0.3 to 0.6; NCT01462344, 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old",
        "record": "/library/comparisons/NCT01462344-d2e8b2c9",
        "nct_id": "NCT01462344",
        "kind": "outcome",
        "participants": 6208,
        "risk_difference": {
          "value": 0.0019180456858139457,
          "lower": -0.0025556482419633745,
          "upper": 0.006486125314267965
        },
        "group_1": "27 of 3,107",
        "group_2": "21 of 3,101",
        "difference": "0.2 points",
        "interval": "-0.3 to 0.6",
        "trial_title": "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old"
      },
      {
        "id": "NCT01462344-sae",
        "title": "FSC DPI vs FP DPI: serious adverse events",
        "summary": "56 of 3107 against 54 of 3101; risk difference 0.1 points, 95% interval -0.6 to 0.7; NCT01462344, 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old",
        "record": "/library/comparisons/NCT01462344-sae",
        "nct_id": "NCT01462344",
        "kind": "serious-adverse-events",
        "participants": 6208,
        "risk_difference": {
          "value": 0.0006100796829661449,
          "lower": -0.006051589903612027,
          "upper": 0.007282147742062084
        },
        "group_1": "56 of 3,107",
        "group_2": "54 of 3,101",
        "difference": "0.1 points",
        "interval": "-0.6 to 0.7",
        "trial_title": "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=73",
  "request_id": "0IM61jM8sB8hT7w2"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?